Dermatology

This new research indicates substantial detection of lower-risk disease among patients who are considered to be health-seeking.

These 4 treatments and their biosimilars show no significant differences, though future studies may be necessary to assess long-term efficacy and safety of biosimilars in treating psoriasis.

Andrew Blauvelt, MD, discusses switching therapies for atopic dermatitis (AD) treatment.

Andrew Blauvelt, MD, discusses upadacitinib for the treatment of atopic dermatitis (AD).

A dermatology expert discusses taking a nuanced approach to interpreting the boxed warnings for JAK inhibitor for atopic dermatitis (AD) treatment.

Andrew Blauvelt, MD, provides an overview of the significance of JAK/Stat pathway inhibition in targeting the pathophysiology of atopic dermatology (AD).

Andrew Blauvelt, MD, provides an overview of different treatment options that are available for patients with moderate to severe atopic dermatitis (AD).

Christopher G. Bunick, MD, PhD, shares their clinical approach for switching therapies for atopic dermatitis (AD) treatment.

A dermatology expert provides an overview of the results of the meta-analysis data from the RAD 2023 atopic dermatitis (AD) trial.

Christopher G. Bunick, MD, PhD, discusses underutilized efficacy outcomes in atopic dermatitis (AD) clinical trials.

A dermatology expert discusses how numerical rating scale (NRS) is used in atopic dermatitis (AD) clinical trials.

For this interview segment, Dr. Arkin discussed the biggest points she hopes dermatologists will take away from National Scleroderma Awareness Month this year.

A dermatology expert discusses how the standard of care EASI scores have been improving with newer atopic dermatitis (AD) therapies.

Christopher G. Bunick, MD, PhD, provides an overview of clinical trial outcomes in atopic dermatitis (AD).

Christopher G. Bunick, MD, PhD, discusses what can be done to improve the standard of care for atopic dermatitis (AD).

Experts discuss how to improve recognition and referral for rare dermatologic conditions in the ER setting.

Boni Elewski, MD, and Benjamin Kaffenberger, MD, and Carly Elston, MD, provide their clinical recommendations regarding future treatments for rare dermatological disorders.

Ted Lain, MD, shares his approach to evaluating patients with a vitiligo diagnosis and the search for concomitant disease.

A patient with vitiligo talks with Heather Woolery-Lloyd, MD, about her personal journey to diagnosis and struggles with the disease.

Drs Keegan and Cameron discuss patient-specific considerations for selecting optimal atopic dermatitis treatment strategies.

Off-label use of JAK inhibitors can prove beneficial in the treatment of several dermatologic conditions.

Experts discuss spesolimab, an IL-36 inhibitor, that was recently FDA approved for treatment of GPP.

Experts discuss the use of biologics in the treatment of rare dermatologic disorders.

In this interview, Marinkovich discussed the implications of the FDA’s landmark approval of B-VEC topical gene therapy for patients with the “butterfly disease.”

In this interview, Stucky discussed his team’s research into an uptick in oral minoxidil prescribing rates for hair loss that had immediately followed the publication of a New York Times article.